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Summary
To investigate the role of signaling by the small GTPase Ral, we have generated mice deficient for RalGDS, a guanine
nucleotide exchange factor that activates Ral. We show that RalGDS is dispensable for mouse development but plays a
substantial role in Ras-induced oncogenesis. Lack of RalGDS results in reduced tumor incidence, size, and progression
to malignancy in multistage skin carcinogenesis, and reduced transformation by Ras in tissue culture. RalGDS does not
appear to participate in the regulation of cell proliferation, but instead controls survival of transformed cells. Experiments
performed in cells isolated from skin tumors suggest that RalGDS mediates cell survival through the activation of the
JNK/SAPK pathway. These studies identify RalGDS as a key component in Ras-dependent carcinogenesis in vivo.S I G N I F I C A N C E
Ras oncogenes are mutated in around 15% of human tumors, so it is important to delineate the oncogenic signaling pathways
activated by this GTPase. Ras has multiple effectors, including Raf protein kinases, phosphoinositide-3 kinases, and guanine nucleo-
tide exchange factors for the small GTPases Ral and Rac. While most studies have focused on the role of Raf and PI3-kinase signaling,
there is increasing interest in studying the Ral pathway in oncogenesis. Although previous evidence using overexpression and
dominant negative approaches in tissue culture has suggested that Ral is involved in Ras-mediated transformation, the results shown
here using a mouse model of carcinogenesis provide genetic evidence for the involvement of Ral signaling, and suggest that
regulation of cell survival is the mechanism.Introduction
Through their interaction with different effector proteins, small
GTPases of the Ras family control a wide range of cellular
functions, including proliferation, differentiation, survival, and
cell movement. Of particular interest in oncogenic signaling by
small GTPases has been the mechanism used by oncogenic
Ras to transform cells. The identification of multiple proteins
that preferentially interact with active Ras raises the potential
for multiple effector pathways, and has led to a number of
studies attempting to elucidate the critical oncogenic signaling
pathways downstream of Ras (for recent review, see Repasky
et al., 2004).
The activity of small GTPases is modulated by the opposing
effects of the guanine nucleotide exchange factors (GEFs),
which promote the formation of the active GTP bound state in
response to extracellular signals, and the GTPase accelerator
proteins (GAPs), which terminate GTPase signaling by facilitat-
ing GTP hydrolysis to GDP. Interestingly, several GEFs appear
to be effector proteins of other small GTPases, thereby provid-
ing a link between the activation of one small GTPase and an-
other. The RalGEF family of proteins control the activity of RalA
and RalB, and at least three members, RalGDS, Rgl, and Rgl2/CANCER CELL : MARCH 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INRlf, have a Ras binding domain and therefore may be Ras ef-
fectors (D’Adamo et al., 1997; de Bruyn et al., 2000; Shao and
Andres, 2000; Wolthuis and Bos, 1999). Ral proteins can also
be activated by Ras-independent pathways, via interaction
with other small GTPases or in a calcium dependent manner
(Hofer et al., 1998; Linnemann et al., 2002; Rosario et al., 2001;
Wolthuis et al., 1998). RalGEF proteins are widely expressed
in mouse tissues, but to date, it is not clear whether different
members of the family regulate different cellular functions, or if
they act in a tissue or growth factor-specific manner. Insight
into the role of the Ral pathway in Ras-mediated oncogenic
transformation came with the observation that dominant nega-
tive Ral mutants can block Ras-mediated transformation of fi-
broblasts in culture (Urano et al., 1996). Furthermore, the use
of Ras effector loop mutants capable of activating RalGEF pro-
teins without affecting the activity of Raf or PI3K supports a
role for the Ral pathway in Ras-dependent transformation (Rod-
riguez-Viciana et al., 1997; White et al., 1995). Finally, activated
versions of RalGEFs can synergize with ERK and PI3K signal-
ing in transformation assays of cells in culture, and can contrib-
ute to experimental metastasis (Ward et al., 2001). These re-
sults suggest that activation of the Ral pathway alone has a
weak oncogenic effect, but can complement the roles of otherC. DOI 10.1016/j.ccr.2005.01.029 219
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however, it has recently been argued that the role of the Ral
pathway in Ras-dependent transformation could be more criti-
cal in human cells compared to rodent fibroblasts (Hamad et
al., 2002; Rangarajan et al., 2004). Part of the role of Ral in
oncogenesis may be to stimulate transcription from the cyclin
D1 promoter, the c-fos serum response element, and the TATA
binding protein promoter (Henry et al., 2000; Johnson et al.,
2000; Murai et al., 1997). Additionally, Ral has been implicated
in the regulation of the AFX and c-jun transcription factors,
which are phosphorylated in response to Ral signaling and
might regulate cell proliferation (de Ruiter et al., 2000; Kops et
al., 1999). Aside from its role in cell transformation, the pres-
ence of Ral GTPases in both the plasma membrane and trans-
port vesicles (Bielinski et al., 1993; Feig et al., 1996) suggests
that this pathway is involved in membrane trafficking. In fact,
GTP-bound Ral interacts with Sec5 (Brymora et al., 2001;
Moskalenko et al., 2002), a component of the exocyst complex
implicated in the delivery of secretory vesicles to specific sites
in the plasma membrane (Hsu et al., 1999). The importance of
Ral in intracellular trafficking is also reflected in its ability to
regulate endocytosis of EGF and insulin receptors (Nakashima
et al., 1999). Finally, Ral plays a role in the control of phospholi-
pase D activation, suggesting the involvement of this GTPase
in the regulation of membrane lipids (Jiang et al., 1995). How-
ever, despite the recent advances in our understanding of the
Ral pathway, the physiological consequences of Ral activation
have yet to be resolved.
Results and discussion
To investigate the role of Ral in oncogenic transformation and
to study Ral guanine nucleotide exchange factors critical for
this cellular response, we have generated mice deficient in
RalGDS, one of the RalGEFs that regulate Ral activity. A
targeting vector was designed in which loxP sites flanked ex-
ons 9 to 15 of RalGDS (Figure 1A). These exons comprise part
of the catalytic domain of RalGDS and residues involved in the
binding of the exchange factor to Ras. Embryonic stem cells
in which the homologous recombination event had occurred
were transiently transfected with Cre recombinase to excise
the floxed sequences, resulting in a RalGDSn allele that lacks
exons 9 to 15 (Figures 1A and 1B). Cells carrying this allele
were used for the generation of chimeric mice that transmitted
the disrupted allele through the germline (Figure 1C). Inter-
crossing of RalGDS+/− mice yielded the expected Mendelian
ratios, indicating that disruption of RalGDS does not result in
embryonic lethality. Moreover, male and female RalGDS−/−
mice are fertile, and no major defects have been observed in
any of the organs analyzed, suggesting that RalGDS is dis-
pensable during mouse development. Experiments in both
Drosophila and Xenopus have shown that disruption of the Ral
signaling pathway through expression of Ral mutants results in
developmental defects, probably due to a role of Ral in regulat-
ing the actin cytoskeleton (Lebreton et al., 2003; Sawamoto et
al., 1999). Although the lack of developmental defects in the
RalGDS mutant mice can be due to the differences between
mice, Drosophila, and Xenopus, it is more likely that it reflects
different consequences of affecting a single Ral exchange220factor rather than blocking the action of all Ral exchange
factors through expression of dominant negative Ral. Other
members of the RalGEF family may compensate for the ab-
sence of RalGDS during mouse development, since Northern
blot analysis has shown an overlapping pattern of expression
for several members of the RalGEF family (Albright et al., 1993;
Shao and Andres, 2000; Wolthuis et al., 1996).
Northern blot analysis of mouse embryonic fibroblasts
(MEFs) isolated from RalGDS−/− mice shows the presence of a
smaller RalGDS transcript derived from the targeted allele (Fig-
ure 1D). Lack of appropriate antibodies prevents us from deter-
mining whether this transcript results in the expression of a
truncated protein. However, transfection of a cDNA plasmid
encoding the predicted protein resulting from the gene
targeting event shows that the truncated RalGDS protein does
not bind to Ras and is also unable to activate Ral (Supplemen-
tal Data and Figure 1E). Therefore, if this protein is expressed
in the RalGDS−/− mice, it would not respond to Ras-mediated
signaling. In agreement with these data, we found that growth
factor-mediated activation of Ral was impaired in MEFs iso-
lated from RalGDS−/− embryos compared to cells isolated from
wild-type littermates (Figure 1F). Similarly, we observed that
12-O-tetradecanoylphorbol-13-acetate (TPA) treatment induced
Ral activation in the skin of wild-type animals, but this activa-
tion was reduced in RalGDS−/− mice (Figure 1G).
To assess the role of RalGDS in Ras-dependent tumor for-
mation, we used a well-established chemical carcinogenesis
protocol where tumors are initiated in epidermal keratinocytes
by topical application of 7,12-dimethylbenz[a]anthracene (DMBA)
and subsequently promoted by TPA treatment. This procedure
results in the development of benign papillomas with a high
incidence of H-Ras mutations (Quintanilla et al., 1986). Some
of these tumors progress to squamous cell carcinomas, which
can undergo epithelial-mesenchymal transition to spindle cell
carcinomas. In RalGDS+/+ mice, tumors appear within 7 weeks
of DMBA application, with 50% of the animals being affected
by week 8–9. However, in the RalGDS−/− group, we observed
a delay of four weeks in the onset of papillomas (Figure 2A).
The resistance to tumor development in RalGDS−/− mice was
also reflected in the number of papillomas per animal, which
was reduced by 4-fold compared to wild-type littermates (Fig-
ures 2B and 2D). Finally, RalGDS deficiency also affected tu-
mor growth, with a significant reduction in the size of the papil-
lomas that developed in RalGDS−/− mice. This impairment in
tumor growth was most evident 15 and 18 weeks after tumor
initiation (Figure 2C). To examine whether loss of functional
RalGDS would affect transformation by oncogenic Ras in tis-
sue culture, MEFs isolated from RalGDS+/+ and RalGDS−/−
embryos were first immortalized by infection with a retrovirus
encoding SV40 large T oncoprotein, and then pools of immor-
talized cells were infected with a retrovirus expressing H-RasV12
oncoprotein. Figure 2E shows that oncogenic Ras produced
50% fewer foci in RalGDS−/− cells compared with wild-type
fibroblasts. Reinstatement of RalGDS expression in the im-
mortalized RalGDS−/− cells by infection with a retrovirus en-
coding RalGDS restored the induction of transformed foci by
H-RasV12 to that obtained by infection of wild-type cells. Alto-
gether, these data indicate an important role for RalGDS in
Ras-dependent cell transformation and extend previous obser-
vations in the requirement of Ral signaling in Ras-driven onco-
genesis to an in vivo setting.CANCER CELL : MARCH 2005
A R T I C L EFigure 1. Generation of mutant mice
A: Diagram of the targeting strategy. Schematic
representation of the RalGDS allele, targeting
construct, and the expected alleles after re-
combination. Arrows indicate the positions of
the PCR primers used to genotype mice. Gray
boxes represent exons, black triangles represent
loxP sites, the black box represents a diphtheria
toxin cassette, and the patterned boxes repre-
sent the neomycin cassette.
B: Southern blot of BamHI-digested DNA show-
ing homologous recombination in the RalGDS
locus. An XmaI-HincII cDNA probe comprising
exons 4 and 5 was used.
C: PCR of tail biopsies from litters obtained from
RalGDS+/− matings.
D: Northern blot of RNA isolated from mouse
embryonic fibroblast of the indicated geno-
types.
E: Activity of truncated RalGDS. Pulldown analy-
sis of RalA activity in lysates from 293 cells trans-
fected with prk5-myc-RalGDS (30 or 60 ng) and
prk5-myc-RalGDS (700 ng) in the presence or
absence of H-RasV12. It was necessary to
transfect different amounts of myc-RalGDS and
RalGDS plasmids to ensure similar expression
levels of the proteins.
F: Pulldown analysis of RalA activity in protein
extracts from RalGDS+/+ or RalGDS−/− MEFs after
PDGF stimulation. To measure Ral activation, Ral
bands were quantified using ImageQuant soft-
ware. The GTP/GDP ratios relative to nontreated
cells are shown.
G: RalA activity in skin treated once with PMA;
extracts were made from skin isolated from
three separate RalGDS−/− mice—one RalGDS+/−
and one RalGDS+/+.As activated versions of RalGDS have been previously
shown to be involved in experimental metastasis, we investi-
gated the role of RalGDS in tumor progression. Tumors dis-
sected from the different groups of mice were subjected to his-
topathological analysis. Papillomas isolated from RalGDS+/+
and RalGDS−/− mice were histologically similar. However, we
observed significant differences in the frequency of malignant
conversion between RalGDS+/+ and RalGDS−/− tumors. Pro-
gression from papillomas to malignant carcinomas in RalGDS+/+
mice started within 16 weeks after DMBA initiation, and ulti-
mately, 36% of the tumors progressed to malignancy. In con-
trast, no malignant tumors were detected before week 28 in
the RalGDS−/− group, and only 9% of the epidermal lesions
had a malignant phenotype (Table 1). These data suggest that
RalGDS is not only required for Ras-dependent tumor forma-
tion, but also influences tumor progression.
To determine the reason for a reduced tumor growth in
RalGDS−/− mice, we have analyzed the consequences of PMA
and DMBA treatment in the skin of wild-type and RalGDS-defi-CANCER CELL : MARCH 2005cient mice. DMBA treatment induces formation of adducts in
skin DNA that lead to transforming mutations. We tested papil-
lomas isolated from RalGDS−/− mice and control littermates for
the presence of Ras mutations. A to T transversions in Ras
codon 61 are the most frequent mutations found in two-stage
skin carcinogenesis induced papillomas (Quintanilla et al.,
1986). This mutation was found in RalGDS−/− papillomas to the
same extent as in RalGDS+/+ tumors (data not shown), sug-
gesting that the mechanism of mutagenesis after DMBA treat-
ment is not altered in the absence of RalGDS.
This result does not explain the reduced incidence of tumors
in RalGDS−/− mice; therefore, we measured the levels of cell
proliferation and apoptosis in papillomas isolated from the dif-
ferent groups of mice. Animals were injected with 5-bromo-2-
deoxyuridine (BrdU) and the level of proliferating cells within
the tumors quantified. As shown in Figures 3A and 3B, the
number of proliferating cells is similar for papillomas isolated
from the three different genotypes. However, when the levels
of cell death in papillomas isolated from RalGDS+/+ and221
A R T I C L EFigure 2. Skin carcinogenesis in wild-type and
RalGDS mutant mice
A: Incidence of tumors in wild-type and RalGDS
mutant mice.
B: Average number of tumors per mice. The dif-
ference in tumor number between RalGDS+/+
and RalGDS−/− groups is statistically significant
(p < 0.001, Bonferroni’s multiple comparison
test).
C: Rate of tumor growth. The difference in
growth rate between RalGDS+/+ and RalGDS−/−
groups is statistically significant (p < 0.0001, χ2
test).
D: Appearance of RalGDS mice and wild-type
littermates 19 weeks after DMBA initiation.
E: Transformation of immortalized MEFs in cul-
ture. SV40 large T immortalized MEFs from
RalGDS+/+ and RalGDS−/− littermates were in-
fected with a retrovirus expressing RalGDS or
empty vector, and pools of drug-resistant clones
isolated and then infected with a retrovirus ex-
pressing oncogenic H-RasV12. Transformed foci
were counted 10–14 days after infection. The
number of foci in RalGDS+/+ cells infected with
H-RasV12 was set to unity and the number of foci
in other conditions compared to this (mean ± SD
of 4 experiments is shown). The differences in
the foci number between KO and WT (*, p <
0.001) and KO+GDS and KO (**, p < 0.05) are
statistically significant by the Student’s t test
analysis.sponse to the apoptotic stimuli of UV and H2O2 (Figure 3E). (reviewed in Lin, 2003). Therefore, we investigated whether dif-
Table 1. Histological analysis of skin tumors from RalGDS+/+, RalGDS+/−, and RalGDS−/− mice subjected to DMBA/TPA treatment
RalGDS+/+ RalGDS+/− RalGDS−/−
n % n % n %
Benign lesions 38 64% 21 58% 32 91%
Malignant lesions 21 36%* 15 42% 3 9%*
Carcinomas in situ (8) (38%) (12) (80%) (0) (0%)
Squamous cell carcinomas (13) (62%) (3) (20%) (3) (100%)
Tumors were isolated from 15 RalGDS+/+, 11 RalGDS+/−, and 10 RalGDS−/− animals.
*The differences in the rate of malignant conversion between RalGDS+/+ and RalGDS−/− are statistically significant (p < 0.005; χ2 test).RalGDS−/− mice were examined by TUNEL, a significant differ-
ence between animal groups was observed. There was a
4-fold increase in the number of apoptotic cells per millimeter
of basement membrane in RalGDS−/− papillomas compared to
tumors isolated from the RalGDS+/+ mice, while the apoptotic
index was similar in papillomas from heterozygous and wild-
type animals (Figures 3C and 3D). Consistent with the observa-
tion that there was a higher rate of apoptosis in RalGDS−/−
tumors, we found that a restoration of RalGDS in a tumor cul-
tured from a RalGDS−/− mouse resulted in a decreased re-222Interestingly, in the light of the known requirement for TNF-α in
this model of skin carcinogenesis (Moore et al., 1999), the ab-
sence of RalGDS did not affect TNF-α-induced apoptosis, sug-
gesting that RalGDS does not function to protect tumor cells
against apoptosis induced by this cytokine (data not shown).
Ral signaling has been shown to be a regulator of the JNK/
SAPK signaling pathway (de Ruiter et al., 2000). The JNK/
SAPK pathway has been shown to be implicated in the regula-
tion of apoptotic cell death, and may have either pro- or anti-
apoptopic effects, depending on the system being analyzedCANCER CELL : MARCH 2005
A R T I C L EFigure 3. Proliferation and apoptosis in skin
tumors
A: BrdU staining (green) of large papillomas (>3
mm in diameter) isolated from the indicated
mice. Keratin 14 is shown in red as a marker for
the epithelial compartment of the tumor. Scale
bars represent 200 m.
B: Average number of proliferating cells per mm
of basement membrane (mean ± SD is shown).
Ten papillomas from each genotype were ex-
amined.
C: TUNEL staining (green) of large papillomas
(>3 mm in diameter) isolated from the indicated
mice. Keratin 14 is shown in red as a marker for
the epithelial compartment of the tumor. Scale
bars represent 100 m.
D: Average number of apoptotic cells per mm
of basement membrane (mean ± SD is shown).
Ten tumors of each genotype were examined.
* indicates p < 0.0005 by the Student’s t test
analysis.
E: Apoptosis in RalGDS−/− tumor cells. Cells ob-
tained from an explanted tumor isolated from
a RalGDS−/− mouse and reconstituted with
RalGDS where treated for 7 hr with the stimuli
shown and the percentage of apoptosis deter-
mined by counting pyknotic nuclei (mean ± SD
of four experiments is shown). * indicates p <
0.01 by the Student’s t test analysis.ferences in the activation of the JNK/SAPK pathway might be
responsible for the enhanced susceptibility to some apo-
ptopic stimuli in RalGDS−/− cells. As shown in Figure 4A, UV
light, but not TNF-α, induces JNK activation in RalGDS−/− cells,
but the activation of this pathway is more sustained when the
expression of RalGDS is restored, showing that prolonged acti-
vation of JNK/SAPK signaling requires RalGDS function. These resulted in an increase in apoptotic cell death to similar levels
Figure 4. RalGDS mediates cell survival through
the activation of the JNK pathway
A: Activation of JNK in RalGDS−/− and RalGDS
reconstituted tumor cells upon UV light irradia-
tion. JNK activation was determined in a West-
ern blot using phosphospecific antibodies.
B: UV light and TNF-α-induced apoptosis after
treatment with the JNK inhibitor SP600125. The
inhibitor was added to the cells 90 min before
UV or TNF-α treatment. For each treatment, the
percentage of cell death in the presence of ve-
hicle was set to unity and the percentage of
cell death after treatment with inhibitor com-
pared to this (mean ± SD of 4 experiments is
shown).
C: Jun phosphorylation after treatment with the
JNK inhibitor SP600125. RalGDS reconstituted
cells were treated as in B and Jun phosphoryla-
tion determined using phosphospecific anti-
bodies.CANCER CELL : MARCH 2005results corroborate previous data indicating that the Ral path-
way regulates the activity of JNK/SAPK (de Ruiter et al., 2000).
To determine whether JNK activation is responsible for the in-
creased survival in RalGDS reconstituted cells, we blocked
JNK activation with SP600125, a reversible JNK inhibitor (Ben-
nett et al., 2001). Following UV light irradiation, JNK inhibition223
A R T I C L Ein both RalGDS−/− and reconstituted cells, showing that in this
system, JNK/SAPK signaling provides a survival signal. Con-
sistent with the lack of JNK/SAPK activation by TNF-α,
SP600125 had no effect on cell death induced by this cytokine
(Figure 4B). These results show that RalGDS signaling to JNK/
SAPK activation mediates protection against some apoptotic
stimuli, but not others, and argue that the increased apoptosis
that we see in tumors of RalGDS−/− mice may be due to a
defect in JNK/SAPK activation. In a number of other tumor sys-
tems, JNK/SAPK signaling has been shown to provide a sur-
vival signal (Hess et al., 2002), and of particular interest in this
context, the JNK/SAPK cascade has been shown to give a sur-
vival signal in mouse skin carcinogenesis protocols (Chen et
al., 2001). Further experiments will be needed to determine the
mechanism of JNK/SAPK survival signaling in tumor cells. It
has been shown that cyclin D1 is a c-jun target gene, and ex-
pression of this cyclin is also Ral-dependent (Albanese et al.,
1995; Henry et al., 2000). Deletion of cyclin D1 in mice results
in inhibition of Ras-dependent tumor formation (Robles et al.,
1998), a similar phenotype to that observed in the RalGDS−/−
mice. Although our results cannot exclude the involvement of
cyclin D1 in the reduced tumorigenesis of RalGDS−/− mice, the
normal levels of cell proliferation in tumors isolated from these
animals (Figures 3A and 3B) suggest this is not the case.
Taken together, our results show that RalGDS is required for
Ras-induced tumor formation, and suggest that it regulates tu-
mor growth by providing a survival signal to tumor cells. Al-
though tissue culture experiments have suggested that activa-
tion of RalGEF proteins and the Ral pathway are required for
proliferation in a variety of cell types (Goi et al., 1999; Rosario
et al., 2001; Wolthuis et al., 1997), we cannot detect any im-
pairment in cell proliferation in RalGDS-deficient papillomas
(Figures 3A and 3B). This might be due to different cellular
requirements in tissue culture and in an in vivo situation. Our
data, however, support a role for RalGDS in tumor cell survival.
A role for the Ral pathway in cell survival has been previously
suggested for transformed cells (Chien and White, 2003).
The identification of numerous binding partners for activated
Ras and consequently the possibility of multiple signaling path-
ways downstream of Ras raises the question of which path-
ways are critical in oncogenesis (see Repasky et al., 2004).
While there is a large body of evidence supporting a key role
for Raf/MAPK pathway in oncogenic Ras signaling, for exam-
ple the restriction of Ras and BRAF mutations to the same tu-
mor types and the mutual exclusivity of Ras and BRAF muta-
tions (Davies et al. 2002), questions have been raised about the
significance of Ras signaling through the Raf/MAPK pathway
during carcinogenesis, because some cells containing onco-
genic Ras alleles have reduced activation of ERK MAP kinases
(Tuveson et al., 2004). Such observations, together with the
potential for multiple Ras signaling pathways, suggest that
other Ras-dependent pathways could be critical in cell trans-
formation. Our data show that Ras signaling through RalGDS
is required for oncogenic transformation. Similarly, genetic ab-
lation of other potential Ras effectors, Tiam1, an exchange
factor for the Rho-family small GTPase Rac, (Malliri et al.,
2002), and recently Phospholipase-C epsilon (Bai et al., 2004),
has been shown to reduce tumor formation in the DMBA/TPA
skin carcinogenesis model. Therefore, it appears that at least
four Ras signaling pathways, Raf, RalGDS, Tiam1, and phos-
pholipase-C epsilon, are involved in oncogenic Ras signaling.224It is possible that different Ras effectors cooperate in the onco-
genic process by regulating different aspects of tumor biology.
Interestingly, genetic ablation of either Tiam1 (Malliri et al.
2002), phospholipase-C epsilon (Bai et al., 2004), or RalGDS
results in viable mice, whereas ablation of Raf-1 or BRAF leads
to death of embryos (Wojnowski et al., 1997; Wojnowski et al.,
1998); these observations raise the possibility that Tiam1, phos-
pholipase-C epsilon, or RalGDS may be better therapeutic
targets in cancer, because their inhibition might be less toxic
than the inhibition of Raf signaling.
The data we present here suggests that RalGDS is an impor-
tant effector of Ras-mediated oncogenesis in a mouse model
system. Recent work from Hamad et al. (2002) and Rangarajan
et al. (2004) suggests that the RalGDS pathway may be more
critical to transformation by oncogenic Ras in human cells than
mouse; however, their studies were all carried out in tissue cul-
ture systems and may therefore have missed a role for Ral sig-
naling in rodent tumor induction in vivo. While our data provide
evidence for RalGDS involvement in Ras-dependent tumor for-
mation, further studies will be needed to evaluate the require-
ments for RalGDS in other oncogenic pathways not dependent
on Ras activation; however, preliminary studies in p53 deficient
mice indicate that ablation of RalGDS does not affect the inci-
dence of tumors (data not shown).
Experimental procedures
Generation of RalGDS mutant mice
Mouse RalGDS genomic clones were obtained by screening a 129/SvJ BAC
library (Incyte). The RalGDS targeting vector was constructed using a DNA
fragment extending from intron 7 to the 3# untranslated region, which was
then cloned into the pKO scrambler 901 vector (Stratagene). A neomycin
cassette flanked by two loxP sites was cloned upstream of exon 16, intro-
ducing a new BamHI site for genotyping purposes. A third loxP site was
located in intron 8. The targeting vector also contains a diphtheria toxin
selection cassette (Figure 1A). This construct was electroporated into RW4
ES cells (Incyte) and homologous recombination was checked by Southern
blot analysis after BamHI digestion using a cDNA probe containing exons
4 and 5 of RalGDS. Positive clones were then transiently transfected with
PcrePac vector to eliminate the neomycin cassette. As a result of Cre-medi-
ated recombination, two different targeted alleles were obtained (Figure 1A):
a RalGDS floxed allele in which loxP sites flank exons 9 to 15 and a RalGDS
null allele (RalGDSn) that lacks the exons 9–15. Cells carrying the RalGDSn
allele were injected into MF-1 blastocysts, and germline-transmitting chim-
eric mice were obtained. Animals with a mixed MF-1/129SvJ background
were used throughout the experiments.
Ral pulldown experiments
For pulldown assays in MEFs, cells were starved for 16 hr in the absence
of serum and then stimulated for the indicated time points using 25 ng/ml
PDGF (Sigma). Cells were washed once in PBS and lysed in PBS containing
1% Triton X-100, 40 µg/ml phenylmethylsulfonyl fluoride (PMSF), 10 mM
sodium fluoride, 10 mM pyrophosphate, and 1 mM sodium vanadate. Ly-
sates containing 200 g of protein were incubated for 1 hr at 4°C with
glutathione-Sepharose beads that had been precoupled to recombinant
glutathione S-transferase (GST)-RalBP1 RalBD as described previously
(Wolthuis et al., 1998). The beads were then washed once with lysis buffer
and twice with 25 mM Tris (pH 7.2), boiled, and the samples analyzed by
Western blotting with an anti-Ral A antibody (Pharmingen).
For pulldown assays in skin extracts, mice were shaved and treated with
150 l 10−4 M 12-O-tetradecanoylphorbol-13-acetate (TPA, Sigma). 24 hr
later, skin was dissected and snap frozen. Tissue was then powdered in
liquid nitrogen using a pestle and mortar, lysed in pulldown buffer, and ly-
sates processed as above.CANCER CELL : MARCH 2005
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The backs of age-matched groups of mice (15 animals of each genotype),
consisting of littermates generated from intercrosses of RalGDS+/− mice on
a mixed MF-1/129SVj background, were shaved, and the next day animals
were topically dosed with 150 l of 125 g/ml 7,12-Dimethylbenzanthra-
cene (DMBA, Sigma). Starting one week later, mice were treated twice
weekly for 20 weeks with 150 l 10−4 M 12-O-tetradecanoylphorbol-13-
acetate (TPA, Sigma). Tumor incidence and multiplicity in the different ani-
mal groups was recorded weekly. Mice were killed if distressed, if any indivi-
dual tumor became ulcerated or reached a diameter of 1.5 cm, or at the
termination of the experiment (50 weeks after initiation). The experiment
was performed twice with similar results.
Focus formation assay
Passage 2 MEFs were immortalized by infection with a retrovirus encoding
SV40 large T antigen, and pools of drug-resistant clones containing at least
70–80 independent infection events were isolated. These cell pools were
then infected either with an empty vector or with a RalGDS containing ret-
rovirus and drug-resistant pools selected as described above. Cells were
then transformed by infection with a retroviral vector encoding H-RasV12
and the number of foci determined 10–14 days after infection.
Histology and immunohistochemistry
Tumors were dissected and fixed in 10% buffered formalin or embedded in
OCT compound (Sakura) and frozen as required. The tumors were then
histologically classified by hematoxylin and eosin staining of paraffin sec-
tions. The degree of hyperplasia and cytological atypia were assessed as
mild, moderate, and severe, according to established guidelines (Arbeit et
al., 1994; Hennings et al., 1993; van Hogerlinden et al., 1999). Tumors were
classified as carcinomas when there was clear evidence of stromal invasion,
with reduced nuclear polarization and disordered keratinization, associated
with stromal fibroblastic reaction (desmoplasia) and/or evidence of infiltra-
tion into the panniculus carnosus muscle layer in the subcutaneous tissue.
For proliferation analysis, mice received an intraperitoneal BrdU injection
(1 mg in 200 l PBS) 1 hr before sacrifice. Detection of BrdU incorporation
was performed in frozen sections using an in vivo proliferation detection
kit (Roche) according to manufacturer’s instructions. Apoptotic cells were
detected in deparaffinized sections by TUNEL using an in situ cell death
detection kit (Promega). The number of TUNEL- or BrdU-positive cells from
several independent fields was evaluated per mm of basement membrane
by confocal microscopy. The antibody for detection of keratin 14 was ob-
tained from Babco.
Apoptosis induction
A cell line was obtained by explanting a skin tumor isolated from a p53+/−
RalGDS−/− mouse. These cells were infected either with an empty retrovirus
or with one encoding RalGDS, and pools of drug-resistant clones contain-
ing at least 50 independent infection events were isolated. For apoptosis
induction, cells were starved in the absence of serum for 24 hr and then
treated with 30 nM hydrogen peroxide (H2O2), 30 nM TNF-α in the presence
of 5 M cyclohexamide, or exposed to ultraviolet irradiation (40 mJ/cm2).
Cells were fixed 7 hr later with 4% paraformaldehyde and stained with
DAPI. The percentage of apoptotic cells was determined by counting the
number of pyknotic nuclei in 10 consecutive fields. For the analysis of JNK
effect on apoptotic cell death, 40 M SP600125 was added to the cells 90
min prior to apoptotic cell death stimuli.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/3/219/DC1/.
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